Glioma remains one of the deadliest brain cancers, characterized by aggressive growth and limited treatment options. In a new study, researchers from Ningxia Medical University uncovered that choline ...
Scientists have discovered that increased expression of a novel long non-coding RNA drives glioblastoma cell growth alongside ...
Cohort 1, osimertinib monotherapy. Cohort 2, a combination of osimertinib and savolitinib therapy. The cutoff date: May 28, 2024. FAS, Full Analysis Set; PD, Progressive disease. [1] Patients with MET ...
1d
Lung Cancer Research Foundation Grants Team Science Award Focused on Curing EGFR-Mutant Lung Cancers
The Lung Cancer Research Foundation (LCRF) announces the first recipients of its LCRF Team Science Award on Advancing Therapies Toward Curing EGFR Mutated Lung Cancers. The project, "A novel ...
Patients with EGFR-mutated non-small cell lung cancer (NSCLC) who progressed on first-line osimertinib (Tagrisso) had better progression-free survival (PFS) in second line when they continued ...
Zacks Investment Research on MSN
BDTX: What silevertinib data say about EGFR NSCLC upside
Black Diamond Therapeutics, Inc. BDTX is building its equity story around a single, high-leverage asset: silevertinib, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results